1R3 Stock Overview
A research and development company, develops diagnostic products for detecting breast cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Izotropic Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.015 |
| 52 Week High | CA$0.14 |
| 52 Week Low | CA$0.015 |
| Beta | 1.79 |
| 11 Month Change | -45.00% |
| 3 Month Change | -59.90% |
| 1 Year Change | -84.25% |
| 33 Year Change | -97.56% |
| 5 Year Change | -89.80% |
| Change since IPO | -92.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1R3 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -43.4% | 1.4% | 2.5% |
| 1Y | -84.3% | -4.6% | 8.6% |
Return vs Industry: 1R3 underperformed the German Medical Equipment industry which returned -4.2% over the past year.
Return vs Market: 1R3 underperformed the German Market which returned 8.8% over the past year.
Price Volatility
| 1R3 volatility | |
|---|---|
| 1R3 Average Weekly Movement | 35.9% |
| Medical Equipment Industry Average Movement | 6.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1R3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1R3's weekly volatility has increased from 30% to 36% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Bob Thast | izocorp.com |
Izotropic Corporation, a research and development company, develops diagnostic products for detecting breast cancers. It develops and commercializes IzoView, a CT diagnostic imaging device with a platform of targeted uses. Izotropic Corporation was incorporated in 2016 and is headquartered in Surrey, Canada.
Izotropic Corporation Fundamentals Summary
| 1R3 fundamental statistics | |
|---|---|
| Market cap | €1.92m |
| Earnings (TTM) | -€1.59m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs 1R3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1R3 income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.35m |
| Earnings | -CA$2.35m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.041 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -46.7% |
How did 1R3 perform over the long term?
See historical performance and comparison